Victory Capital Management Inc. Purchases 1,876 Shares of Sanofi (NASDAQ:SNY)

Victory Capital Management Inc. raised its position in shares of Sanofi (NASDAQ:SNY) by 27.6% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 8,669 shares of the company’s stock after acquiring an additional 1,876 shares during the quarter. Victory Capital Management Inc.’s holdings in Sanofi were worth $500,000 as of its most recent SEC filing.

A number of other institutional investors have also bought and sold shares of SNY. Barrow Hanley Mewhinney & Strauss LLC boosted its position in Sanofi by 113.8% during the second quarter. Barrow Hanley Mewhinney & Strauss LLC now owns 5,943,547 shares of the company’s stock valued at $288,381,000 after acquiring an additional 3,164,092 shares during the last quarter. Magnetar Financial LLC boosted its position in Sanofi by 1,153.1% during the second quarter. Magnetar Financial LLC now owns 2,506,286 shares of the company’s stock valued at $121,605,000 after acquiring an additional 2,306,286 shares during the last quarter. Bank of New York Mellon Corp boosted its position in shares of Sanofi by 19.0% during the 2nd quarter. Bank of New York Mellon Corp now owns 8,594,740 shares of the company’s stock worth $417,017,000 after purchasing an additional 1,370,232 shares in the last quarter. Federated Hermes Inc. boosted its position in shares of Sanofi by 26.5% during the 2nd quarter. Federated Hermes Inc. now owns 3,214,141 shares of the company’s stock worth $155,950,000 after purchasing an additional 673,172 shares in the last quarter. Finally, Raymond James & Associates boosted its position in shares of Sanofi by 16.2% during the 2nd quarter. Raymond James & Associates now owns 2,689,876 shares of the company’s stock worth $130,513,000 after purchasing an additional 374,621 shares in the last quarter. Institutional investors own 10.04% of the company’s stock.

Analyst Ratings Changes

SNY has been the topic of a number of research analyst reports. Citigroup raised shares of Sanofi to a “strong-buy” rating in a research report on Tuesday, September 17th. StockNews.com cut shares of Sanofi from a “strong-buy” rating to a “buy” rating in a research report on Thursday, November 7th. Two analysts have rated the stock with a hold rating, two have issued a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $57.50.

Sanofi Price Performance

Shares of NASDAQ SNY opened at $48.49 on Friday. Sanofi has a fifty-two week low of $45.22 and a fifty-two week high of $58.97. The stock has a market cap of $123.06 billion, a price-to-earnings ratio of 24.74, a PEG ratio of 1.23 and a beta of 0.61. The company has a debt-to-equity ratio of 0.17, a quick ratio of 0.65 and a current ratio of 1.00. The firm’s 50-day simple moving average is $52.80 and its 200 day simple moving average is $52.11.

Sanofi (NASDAQ:SNY) last announced its quarterly earnings results on Friday, October 25th. The company reported $1.57 earnings per share for the quarter, beating the consensus estimate of $0.22 by $1.35. Sanofi had a net margin of 9.96% and a return on equity of 27.45%. The business had revenue of $13.44 billion for the quarter, compared to analysts’ expectations of $16.59 billion. During the same quarter last year, the firm earned $2.55 EPS. The firm’s revenue for the quarter was up 12.3% compared to the same quarter last year. As a group, research analysts anticipate that Sanofi will post 4.29 earnings per share for the current fiscal year.

Sanofi Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.